In the V-INITIATE trial, early initiation of Leqvio in ASCVD patients on statin therapy led to significant LDL-C reduction compared to usual care.

New Novartis data from the V-INITIATE trial show that early initiation of Leqvio (inclisiran) in ASCVD patients unable to achieve LDL-C goal on statin therapy led to a significant LDL-C reduction compared to usual care (60% vs. 7%). In the trial, a higher proportion of patients receiving Leqvio reached guideline-recommended LDL-C goals while maintaining statin treatment. These results highlight the need for more aggressive LDL-C lowering in ASCVD patients, as 92% did not reach their LDL-C goal with statins alone. The Leqvio safety profile remained consistent with previous clinical studies and long-term trials.

April 06, 2024
9 Articles